![](/img/cover-not-exists.png)
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Borchmann, Peter, Haverkamp, Heinz, Lohri, Andreas, Mey, Ulrich, Kreissl, Stefanie, Greil, Richard, Markova, Jana, Feuring-Buske, Michaela, Meissner, Julia, Dührsen, Ulrich, Ostermann, Helmut, Keller,Volume:
18
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(17)30103-1
Date:
April, 2017
File:
PDF, 485 KB
english, 2017